Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(1.90) per share which beat the analyst consensus estimate of $(3.64) by 47.76 percent. This is a 73.24 percent increase over losses of $(7.10) per share from the same period last year. The company reported quarterly sales of $212.802 million which beat the analyst consensus estimate of $158.902 million by 33.92 percent. This is a 1.35K percent increase over sales of $14.638 million the same period last year.